REG - Sareum Holdings PLC - Appointment of Joint Corporate Broker

Sareum HoldingsAnnouncement

30/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251030:nRSd4065Fa&default-theme=true

RNS Number : 4065F  Sareum Holdings PLC  30 October 2025

 

Sareum Holdings PLC

 

("Sareum" or the "Company")

Appointment of Joint Corporate Broker

Cambridge, UK, 30 October 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, is pleased to announce the
appointment of Singer Capital Markets as Joint Corporate Broker with immediate
effect. Strand Hanson Limited remains as the Company's Nominated Adviser, and
Oberon Capital as Joint Corporate Broker.

- Ends -

 

For further information:

 

 Sareum Holdings plc

 Stephen Parker, Executive Chairman                  01223 497700

                                                     ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Singer Capital Markets (Joint Corporate Broker)     020 7496 3000

 Phil Davies

 Oberon Capital (Joint Corporate Broker)             020 3179 5300

 Mike Seabrook / Nick Lovering

 ICR Healthcare (Financial PR)                       020 3709 5700

 Jessica Hodgson / Davide Salvi

 

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy, and has recently initiated a preclinical
programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such
as multiple sclerosis and Parkinson's disease.

The Company is the license holder for SRA737, a clinical-stage Checkpoint
kinase 1 inhibitor that targets cancer cell replication and DNA damage repair
mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBCBDGDDDDGUC



            Copyright 2019 Regulatory News Service, all rights reserved